5.44
price down icon1.63%   -0.09
pre-market  Vorhandelsmarkt:  5.44  
loading

Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten

pulisher
Jul 24, 2025

What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe

Jul 24, 2025
pulisher
Jul 24, 2025

EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Is Aldeyra Therapeutics Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-23 18:29:07 - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Aldeyra Therapeutics Inc. stock priceHigh-impact stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare

Jul 18, 2025
pulisher
Jul 17, 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times

Jul 17, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 12, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 08, 2025

Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st

Jul 08, 2025
pulisher
Jul 06, 2025

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st

Jul 06, 2025
pulisher
Jul 02, 2025

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Jul 02, 2025
pulisher
Jun 27, 2025

Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN

Jun 27, 2025
pulisher
Jun 27, 2025

Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail

Jun 27, 2025
pulisher
Jun 26, 2025

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug By Investing.com - Investing.com Canada

Jun 26, 2025
pulisher
Jun 25, 2025

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Jun 25, 2025
pulisher
Jun 21, 2025

When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive

Jun 17, 2025
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):